A new copper transport drug aims to restore memory and clear toxic Alzheimer's proteins, though it targets a highly contentious area of research. Discussions surrounding the article highlight ongoing skepticism toward amyloid-directed therapies, reflecting a deep divide among experts over whether clearing amyloid-beta plaques can effectively treat the disease after decades of failed clinical trials.